An Exploratory Trial of EPI-589 in Amyotrophic Lateral Sclerosis (EPIC-ALS): Protocol for a Multicenter, Open-Labeled, 24-Week, Single-Group Study

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder, with its currently approved drugs, including riluzole and edaravone, showing limited therapeutic effects. Therefore, safe and effective drugs are urgently necessary. EPI-589 is an orally available, small-molecule,...

Descripción completa

Detalles Bibliográficos
Autores principales: Haji, Shotaro, Fujita, Koji, Oki, Ryosuke, Osaki, Yusuke, Miyamoto, Ryosuke, Morino, Hiroyuki, Nagano, Seiichi, Atsuta, Naoki, Kanazawa, Yuki, Matsumoto, Yuki, Arisawa, Atsuko, Kawai, Hisashi, Sato, Yasutaka, Sakaguchi, Satoshi, Yagi, Kenta, Hamatani, Tatsuto, Kagimura, Tatsuo, Yanagawa, Hiroaki, Mochizuki, Hideki, Doyu, Manabu, Sobue, Gen, Harada, Masafumi, Izumi, Yuishin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2023
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926342/
https://www.ncbi.nlm.nih.gov/pubmed/36716091
http://dx.doi.org/10.2196/42032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926342/
https://www.ncbi.nlm.nih.gov/pubmed/36716091
http://dx.doi.org/10.2196/42032

Ejemplares similares